Table 1.
Patient demographic and clinical characteristics on ALAI and PP1M.
| Characteristics | ALAI |
PP1M |
X2 (df) or as stated | p value | ALAI |
PP1M |
X2 (df) or as stated | p value |
|---|---|---|---|---|---|---|---|---|
| All patients | All patients | SCZ patients | SCZ patients | |||||
| n = 109 (%) | n = 173 (%) | n = 71 (%) | n = 120 (%) | |||||
| Male | 51.4 | 64.2 | 4.54 (1) | 0.03* | 59.2 | 63.3 | 0.33 (1) | 0.57 |
| Female | 48.6 | 35.8 | 40.8 | 36.7 | ||||
| Age | ||||||||
| Mean (SD), range | 48.39 (15.09), 24–84 | 46.0 (15.9), 21–97 | Mann–Whitney Z Score = −1.44 | 0.15 | 47.17 (16.17), 24–85 | 46.5 (14.9), 21–75 | Mann–Whitney Z Score = −0.37 | 0.71 |
| White | 43.1 | 39.9 | 0.29 (1) | 0.59 | 32.4 | 40.8 | 1.35 (1) | >0.24 |
| Non White | 56.9 | 60.1 | 67.6 | 59.2 | ||||
| Comorbid substance misuse | 20.2 | 19.7 | 0.01 (1) | 0.91 | 19.7 | 19.2 | 0.009 (1) | 0.93 |
| Inpatient | 60.6 | 41.6 | 9.59 (1) | 0.001* | 57.7 | 39.2 | 6.10 (1) | 0.01* |
| Outpatient | 39.4 | 58.4 | 42.3 | 60.8 | ||||
| Number of total previous admissions | ||||||||
| Mean (SD), range | 4.16 (4.54), 0–24 | 3.76 (4.3), 0–31 | Mann-Whitney Z Score = 0.75 | 0.45 | 3.39 (4.06), 0–22 | 3.73 (4.30), 0–31 | Mann-Whitney Z Score = 0.78 | 0.44 |
| Antipsychotic switched from | ||||||||
| None/not known | 3.7 | 0 | Fishers exact test | 0.000* | 5.6 | 0 | Fishers exact test | 0.000* |
| Oral | 67.9 | 49.1 | 63.4 | 40.0 | ||||
| Depot/LAI | 28.4 | 50.9 | 31.0 | 60.0 | ||||
| Reason for switching | ||||||||
| Refusal/compliance | 67.0 | 42.2 | 34.64 (3) | 0.000* | 64.8 | 41.7 | 18.65 (3) | 0.0003* |
| Poor tolerability | 22.0 | 17.3 | 21.1 | 19.2 | ||||
| Ineffectiveness | 8.3 | 13.9 | 9.9 | 14.1 | ||||
| Other/preference for less frequent LAI | 1.8 | 26.5 | 2.8 | 25.0 |
*
p <0.05.
ALAI, aripiprazole long-acting injectable; LAI, long-acting injectable antipsychotic; PP1M, once-monthly paliperidone palmitate; SD, standard deviation; SCZ, schizophrenia.